EP3720871A4 - TARGETED IMMUNOTOLERANCE - Google Patents

TARGETED IMMUNOTOLERANCE Download PDF

Info

Publication number
EP3720871A4
EP3720871A4 EP18887096.8A EP18887096A EP3720871A4 EP 3720871 A4 EP3720871 A4 EP 3720871A4 EP 18887096 A EP18887096 A EP 18887096A EP 3720871 A4 EP3720871 A4 EP 3720871A4
Authority
EP
European Patent Office
Prior art keywords
immuntolerance
targeted
targeted immuntolerance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP18887096.8A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3720871A1 (en
Inventor
Nathan HIGGINSON-SCOTT
Joanne L. Viney
Jyothsna Visweswaraiah
Erik Robert Sampson
Kevin Lewis Otipoby
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pandion Operations Inc
Original Assignee
Pandion Operations Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2018/034334 external-priority patent/WO2018217989A1/en
Priority claimed from US16/109,875 external-priority patent/US10174091B1/en
Application filed by Pandion Operations Inc filed Critical Pandion Operations Inc
Publication of EP3720871A1 publication Critical patent/EP3720871A1/en
Publication of EP3720871A4 publication Critical patent/EP3720871A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP18887096.8A 2017-12-06 2018-11-28 TARGETED IMMUNOTOLERANCE Withdrawn EP3720871A4 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762595357P 2017-12-06 2017-12-06
US201762595348P 2017-12-06 2017-12-06
US201862675972P 2018-05-24 2018-05-24
PCT/US2018/034334 WO2018217989A1 (en) 2017-05-24 2018-05-24 Targeted immunotolerance
US15/988,311 US10676516B2 (en) 2017-05-24 2018-05-24 Targeted immunotolerance
US201862721644P 2018-08-23 2018-08-23
US16/109,875 US10174091B1 (en) 2017-12-06 2018-08-23 IL-2 muteins
US16/109,897 US10174092B1 (en) 2017-12-06 2018-08-23 IL-2 muteins
PCT/US2018/062780 WO2019112852A1 (en) 2017-12-06 2018-11-28 Targeted immunotolerance

Publications (2)

Publication Number Publication Date
EP3720871A1 EP3720871A1 (en) 2020-10-14
EP3720871A4 true EP3720871A4 (en) 2021-09-15

Family

ID=66751175

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18887096.8A Withdrawn EP3720871A4 (en) 2017-12-06 2018-11-28 TARGETED IMMUNOTOLERANCE

Country Status (3)

Country Link
EP (1) EP3720871A4 (enExample)
JP (1) JP2021505156A (enExample)
WO (1) WO2019112852A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018234810B2 (en) 2017-03-15 2023-05-11 Pandion Operations, Inc. Targeted immunotolerance
US10676516B2 (en) 2017-05-24 2020-06-09 Pandion Therapeutics, Inc. Targeted immunotolerance
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
AU2018378078B2 (en) * 2017-12-06 2024-07-25 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
WO2020236875A1 (en) 2019-05-20 2020-11-26 Pandion Therapeutics, Inc. Madcam targeted immunotolerance
AU2020323893A1 (en) 2019-07-26 2022-02-17 Visterra, Inc. Interleukin-2 agents and uses thereof
TW202136317A (zh) 2019-12-20 2021-10-01 美商再生元醫藥公司 新穎之ｉｌ２促效劑及其使用方法（二）
US11633488B2 (en) 2020-01-10 2023-04-25 Bright Peak Therapeutics Ag Modified IL-2 polypeptides and uses thereof
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
EP4255466A1 (en) 2020-12-04 2023-10-11 Visterra, Inc. Methods of using interleukin-2 agents
WO2023281483A1 (en) 2021-07-09 2023-01-12 Bright Peak Therapeutics Ag Modified tnf-antibodies and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015164815A1 (en) * 2014-04-24 2015-10-29 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
WO2016164937A2 (en) * 2015-04-10 2016-10-13 Amgen Inc. Interleukin-2 muteins for the expansion of t-regulatory cells
WO2018217989A1 (en) * 2017-05-24 2018-11-29 Pandion Therapeutics, Inc. Targeted immunotolerance
WO2019112854A1 (en) * 2017-12-06 2019-06-13 Pandion Therapeutics, Inc. Il-2 muteins and uses thereof
WO2020061142A1 (en) * 2018-09-18 2020-03-26 Pandion Therapeutics, Inc. Targeted immunotolerance

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001227966A1 (en) * 2000-01-20 2001-07-31 Chiron Corporation Methods for treating tumors
WO2004022593A2 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
PE20051053A1 (es) * 2004-01-09 2005-12-12 Pfizer ANTICUERPOS CONTRA MAdCAM
RU2006135112A (ru) * 2004-03-05 2008-04-10 Чирон Корпорейшн (Us) Тест-система in vitro для прогнозирования устойчивости пациента к терапевтическим средствам
US9546203B2 (en) * 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
US10174092B1 (en) * 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015164815A1 (en) * 2014-04-24 2015-10-29 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
WO2016164937A2 (en) * 2015-04-10 2016-10-13 Amgen Inc. Interleukin-2 muteins for the expansion of t-regulatory cells
WO2018217989A1 (en) * 2017-05-24 2018-11-29 Pandion Therapeutics, Inc. Targeted immunotolerance
WO2019112854A1 (en) * 2017-12-06 2019-06-13 Pandion Therapeutics, Inc. Il-2 muteins and uses thereof
WO2020061142A1 (en) * 2018-09-18 2020-03-26 Pandion Therapeutics, Inc. Targeted immunotolerance

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO2019112852A1 *
TOBIAS JAHN ET AL: "An Il12-Il2-Antibody Fusion Protein Targeting Hodgkin's Lymphoma Cells Potentiates Activation Of Nk And T Cells For An Anti-Tumor Attack", PLOS ONE, vol. 7, no. 9, 18 September 2012 (2012-09-18), pages e44482, XP055588597, DOI: 10.1371/journal.pone.0044482 *

Also Published As

Publication number Publication date
JP2021505156A (ja) 2021-02-18
EP3720871A1 (en) 2020-10-14
WO2019112852A1 (en) 2019-06-13

Similar Documents

Publication Publication Date Title
DK3731771T3 (da) V462033dk00
EP3596108A4 (en) TARGETED IMMUNOTOLERANCE
EP3720871A4 (en) TARGETED IMMUNOTOLERANCE
CL2018000524S1 (es) Golilla
DE202018003363U8 (de) Handgelenkssphygmomanometer
EP3634404C0 (en) PYRAZOLE-BASED MAGL INHIBITORS
EP3589248A4 (en) CRYOTHERAPIES
EP3588580A4 (en) SCHOTTKY MOS TRENCH DIODE
DK3351526T3 (da) Diisopentylterephthalat
EP3876986A4 (en) Targeted immunotolerance
EP3697802A4 (en) TRITERPENIC SAPONIN ANALOGUES
EP3634397A4 (en) HETEROCYCLYL POLYMETHINE-BASED IR CHROMOPHORES
DK3568655T3 (da) Rekuperator
DK3571580T5 (da) Load-logical-and-shift-guarded-instruktion
EP3654852A4 (en) TOURNIQUET
DK3612237T3 (da) Genterapi
EP3575467A4 (en) NON-WOVEN FABRIC THREADED
EP3611402A4 (en) SERVO CYLINDER
EP3714787A4 (en) BIOSENSOR
DK3576686T3 (da) Brokbind
DK3568506T3 (da) Offeranode
EP3689701A4 (en) BOGIE
EP3569893A4 (en) CHAIN TENSIONER
EP3687383C0 (fr) Electrogustometre
DK3510051T3 (da) Carboxylalkylchitosan

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200605

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: VISWESWARAIAH, JYOTHSNA

Inventor name: VINEY, JOANNE L.

Inventor name: SAMPSON, ERIK ROBERT

Inventor name: HIGGINSON-SCOTT, NATHAN

Inventor name: OTIPOBY, KEVIN LEWIS

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PANDION OPERATIONS, INC.

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20210813

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/00 20060101ALI20210809BHEP

Ipc: C07K 19/00 20060101ALI20210809BHEP

Ipc: C07K 14/55 20060101AFI20210809BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20250521